- Home
- GDL vs MGNX Comparison
GDL vs MGNX Comparison
Compare GDL & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDL
- MGNX
- Stock Information
- Founded
- GDL 2006
- MGNX 2000
- Country
- GDL United States
- MGNX United States
- Employees
- GDL N/A
- MGNX N/A
- Industry
- GDL Investment Managers
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- GDL Finance
- MGNX Health Care
- Exchange
- GDL Nasdaq
- MGNX Nasdaq
- Market Cap
- GDL 94.9M
- MGNX 99.7M
- IPO Year
- GDL N/A
- MGNX 2013
- Fundamental
- Price
- GDL $8.51
- MGNX $1.36
- Analyst Decision
- GDL
- MGNX Hold
- Analyst Count
- GDL 0
- MGNX 6
- Target Price
- GDL N/A
- MGNX $3.20
- AVG Volume (30 Days)
- GDL 11.2K
- MGNX 829.2K
- Earning Date
- GDL 01-01-0001
- MGNX 11-04-2025
- Dividend Yield
- GDL 6.02%
- MGNX N/A
- EPS Growth
- GDL N/A
- MGNX N/A
- EPS
- GDL N/A
- MGNX N/A
- Revenue
- GDL N/A
- MGNX $165,495,000.00
- Revenue This Year
- GDL N/A
- MGNX N/A
- Revenue Next Year
- GDL N/A
- MGNX N/A
- P/E Ratio
- GDL N/A
- MGNX N/A
- Revenue Growth
- GDL N/A
- MGNX 303.47
- 52 Week Low
- GDL $7.65
- MGNX $0.99
- 52 Week High
- GDL $8.13
- MGNX $4.87
- Technical
- Relative Strength Index (RSI)
- GDL 51.31
- MGNX 33.29
- Support Level
- GDL $8.45
- MGNX $1.82
- Resistance Level
- GDL $8.53
- MGNX $1.69
- Average True Range (ATR)
- GDL 0.06
- MGNX 0.14
- MACD
- GDL 0.00
- MGNX -0.05
- Stochastic Oscillator
- GDL 79.41
- MGNX 5.85
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.